In the E-LIFT trial, 50 T2D patients with NAFLD (≥40 years old) were randomized to empagliflozin (10 mg/d) plus their standard medical treatment for T2D, such as metformin and/or insulin, or to the receipt of only their standard treatment without empagliflozin (control group). The gene discussed is INS; the disease is type 2 diabetes mellitus.